- Home
- HBT vs BBNX Comparison
HBT vs BBNX Comparison
Compare HBT & BBNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HBT
- BBNX
- Stock Information
- Founded
- HBT 1920
- BBNX 2015
- Country
- HBT United States
- BBNX United States
- Employees
- HBT N/A
- BBNX N/A
- Industry
- HBT Major Banks
- BBNX Medical/Dental Instruments
- Sector
- HBT Finance
- BBNX Health Care
- Exchange
- HBT Nasdaq
- BBNX Nasdaq
- Market Cap
- HBT 812.0M
- BBNX 967.6M
- IPO Year
- HBT 2019
- BBNX 2025
- Fundamental
- Price
- HBT $23.74
- BBNX $27.25
- Analyst Decision
- HBT Buy
- BBNX Strong Buy
- Analyst Count
- HBT 5
- BBNX 11
- Target Price
- HBT $28.63
- BBNX $28.09
- AVG Volume (30 Days)
- HBT 32.8K
- BBNX 793.5K
- Earning Date
- HBT 10-20-2025
- BBNX 10-28-2025
- Dividend Yield
- HBT 3.52%
- BBNX N/A
- EPS Growth
- HBT 12.74
- BBNX N/A
- EPS
- HBT 2.48
- BBNX N/A
- Revenue
- HBT $233,255,000.00
- BBNX $88,570,000.00
- Revenue This Year
- HBT $9.02
- BBNX $52.13
- Revenue Next Year
- HBT $32.67
- BBNX $36.07
- P/E Ratio
- HBT $9.61
- BBNX N/A
- Revenue Growth
- HBT 6.87
- BBNX 67.01
- 52 Week Low
- HBT $19.46
- BBNX $8.89
- 52 Week High
- HBT $27.02
- BBNX $30.47
- Technical
- Relative Strength Index (RSI)
- HBT 41.94
- BBNX 58.66
- Support Level
- HBT $23.24
- BBNX $26.13
- Resistance Level
- HBT $24.11
- BBNX $29.22
- Average True Range (ATR)
- HBT 0.61
- BBNX 2.07
- MACD
- HBT -0.00
- BBNX -0.01
- Stochastic Oscillator
- HBT 23.76
- BBNX 46.09
About HBT HBT Financial Inc.
HBT Financial Inc provides a comprehensive suite of business, commercial, wealth management, and retail banking products and services to individuals, businesses, and municipal entities throughout Central and Northeastern Illinois and Eastern Iowa. It operates through one reportable segment: community banking.
About BBNX Beta Bionics Inc. Common Stock
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company product includes the iLet Bionic Pancreas (iLet). The Company operates as a single segment, focused on the development, manufacture and sale of the iLet.